LUKAS SCHEIBLER - 12 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Research Officer
Signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol: APLS
Transactions as of: 12 Jan 2023
Net transactions value: +$1,867,956
Form type: 4
Filing time: 17 Jan 2023, 18:42:48 UTC
Previous filing: 31 May 2022
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+22,580	+55%	$0.000000	63,707	12 Jan 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$1,867,956	+35,472		$52.66	35,472	12 Jan 2023	Common Stock	35,472	$52.66	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F2	This includes 769 shares from 04/29/2022 ESPP purchase.
F3	This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.